Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives

Exemestane (EXE) treats estrogen receptor positive (ER+) breast cancer in postmenopausal women by inhibiting the estrogen‐synthesizing cytochrome P450 CYP19A1. Variability in the severity and incidence of side effects as well as overall drug efficacy may be partially explained by genetic factors, in...

全面介紹

Na minha lista:
書目詳細資料
發表在:Pharmacol Res Perspect
Main Authors: Peterson, Amity, Xia, Zuping, Chen, Gang, Lazarus, Philip
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2017
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464342/
https://ncbi.nlm.nih.gov/pubmed/28603632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.313
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍